Skip to content
Back to Blog
Bio
2026-02-238 min read251

CDMO Special Act 2026 Implementation: Regulatory Changes and Entry Opportunities for Bio SMEs

A comprehensive guide to the CDMO Special Act taking effect in late 2026, covering key regulatory changes, preparation requirements for bio SMEs, and market entry strategies leveraging government support programs.

KITIM Consulting Team

CDMO Special Act 2026: Key Changes Bio SMEs Need to Know

The Special Act on the Promotion and Support of the Bio-pharmaceutical CDMO Industry, passed by the National Assembly in December 2025, is set to take effect in the second half of 2026. With the global CDMO market projected to reach approximately $270 billion by 2030, this legislation marks a pivotal regulatory shift that opens new market entry pathways for Korean bio SMEs.

Key Provisions of the CDMO Special Act

New Registration System for Export Manufacturing

Previously, contract biopharmaceutical manufacturers were subject to the same regulatory requirements as domestic product authorization. The Special Act introduces a dedicated registration system for export-oriented CDMO manufacturing, establishing a streamlined process for export-purpose contract production. This is expected to reduce the manufacturing license timeline from the current 12–18 months to approximately 6–9 months.

Codified GMP Compliance Standards for CDMO Facilities

The Act establishes CDMO-specific GMP compliance certification standards, distinct from conventional pharmaceutical manufacturing GMP. These standards address facility, equipment, and quality management criteria tailored to contract manufacturing operations. Notably, cleaning validation and cross-contamination prevention standards for multi-product changeover operations are explicitly defined, giving SMEs clear benchmarks for facility design.

Legal Framework for Raw Material Certification

For the first time, legal grounds for certification standards covering biopharmaceutical raw materials—including cell lines, culture media, and active pharmaceutical ingredients—have been established. Previously limited to guideline-level recommendations, these standards now carry statutory authority, significantly improving supply chain predictability.

Impact on Bio SMEs

Streamlined Facility Requirements for Export-Focused Sites

Export-dedicated CDMO facilities will benefit from rationalized facility standards compared to domestic manufacturing sites. A key provision exempts facilities from additional domestic requirements when they meet the GMP standards specified by the importer's destination country, reducing the initial capital investment burden.

Faster Export Customs Clearance

The Act introduces a priority customs processing system for CDMO-manufactured biopharmaceutical exports. Once the MFDS-Customs Service information linkage system is established, export clearance times are expected to decrease from the current average of 7–10 days to 3–5 days.

Leveraging the CDMO Regulatory Support Task Force

A dedicated CDMO Regulatory Support Task Force will be established under the Ministry of Food and Drug Safety (MFDS). SMEs can access one-stop support services including pre-authorization consultations, GMP certification guidance, and destination country regulatory intelligence.

Implementation Timeline and Preparation

Roadmap to 2026 Enforcement

  • H1 2026: Public notice and hearings for enforcement decrees and regulations
  • Q3 2026: Finalization and official gazette publication of subordinate legislation
  • Q4 2026: Full enforcement of the Special Act; export manufacturing registration applications open
  • Pre-Implementation Checklist

    Bio SMEs should address the following critical items before the Act takes effect:

  • Facilities: Verify cleanroom classifications, assess multi-product changeover readiness, and establish cleaning validation protocols
  • Personnel: Secure qualified QA/QC managers, develop CDMO-specific workforce training plans
  • Documentation: Revise quality manuals, update SOPs to reflect CDMO standards, and prepare contract manufacturing agreement templates
  • Market Entry Strategy for Bio SMEs

    Step-by-Step GMP Compliance Roadmap

  • Phase 1 (Now – 6 months): Conduct gap analysis against current facility standards and identify remediation items
  • Phase 2 (6–12 months): Complete facility upgrades, install equipment, and execute validation protocols
  • Phase 3 (12–18 months): Apply for GMP compliance certification and register as an export manufacturer
  • Leveraging Government R&D Programs

    Bio CDMO has been designated a priority government R&D investment area for 2026. Strategic utilization of programs such as the MOTIE Bio Manufacturing Innovation Program, MSS Technology Development Grants, and KHIDI Bio-Health R&D initiatives can effectively offset facility investment and technology development costs.

    KITIM Bio GMP Consulting Services

    KITIM provides comprehensive consulting for bio SMEs preparing to enter the CDMO market, including GMP facility gap analysis, regulatory strategy development, and government R&D program linkage. From building a phased preparation roadmap aligned with the Special Act timeline to completing export manufacturing registration, our expert consultants deliver tailored support at every stage. Companies preparing for CDMO market entry are invited to request a consultation through the KITIM website or at contact@kitim.org.

    CDMO Special ActBio Regulatory ReformExport Manufacturing

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.